S
Sergio Ricci
Researcher at University of Pisa
Publications - 87
Citations - 17024
Sergio Ricci is an academic researcher from University of Pisa. The author has contributed to research in topics: Sorafenib & Cancer. The author has an hindex of 28, co-authored 87 publications receiving 14757 citations. Previous affiliations of Sergio Ricci include Bayer.
Papers
More filters
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
Hans von der Maase,Lisa Sengeløv,J. T. Roberts,Sergio Ricci,Luigi Dogliotti,Tim Oliver,Malcolm J. Moore,Annamaria Zimmermann,M. Arning +8 more
TL;DR: Compared with a large randomized phase III study of GC versus MVAC, long-term survival in patients with locally advanced or metastatic transitional cell carcinoma of the urothelium treated with gemcitabine/cisplatin or methotrexate/vinblastine/doxorubicin/c isplatin was similar in both arms.
Journal ArticleDOI
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Ghassan K. Abou-Alfa,Lawrence H. Schwartz,Sergio Ricci,Dino Amadori,Armando Santoro,Arie Figer,Jacques De Greve,Jean-Yves Douillard,Chetan Lathia,Brian Schwartz,Ian Taylor,M. Moscovici,Leonard B. Saltz +12 more
TL;DR: Although single-agent sorafenib has modest efficacy in HCC, the manageable toxicity and mechanisms of action support a role for combination regimens with other anticancer agents.
Journal ArticleDOI
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
Alfredo Falcone,Sergio Ricci,Isa Brunetti,Elisabetta Pfanner,Giacomo Allegrini,C. Barbara,Lucio Crinò,Giovanni Benedetti,W. Evangelista,Laura Fanchini,Enrico Cortesi,V. Picone,Stefano Vitello,Silvana Chiara,Cristina Granetto,Gianfranco Porcile,Luisa Fioretto,Cinzia Orlandini,Michele Andreuccetti,Gianluca Masi +19 more
TL;DR: The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics.
Journal ArticleDOI
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
Giancarlo Agnelli,Gualberto Gussoni,Carlo Bianchini,Melina Verso,Mario Mandalà,Luigi Cavanna,Sandro Barni,Roberto Labianca,Franco Buzzi,Giovanni Scambia,Rodolfo Passalacqua,Sergio Ricci,Giampietro Gasparini,Vito Lorusso,Erminio Bonizzoni,Maurizio Tonato +15 more
TL;DR: Nadroparin reduces the incidence of thromboembolic events in ambulatory patients with metastatic or locally advanced cancer who are receiving chemotherapy, and future studies should focus on patients who are at a high risk for thrombolic events.